Added to YB: 2025-11-18
Pitch date: 2025-11-14
NOVO-B.CO [neutral]
Novo Nordisk A/S
+2.92%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 312.05
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 14/11/2025 - NOVOB – Que Metsera, sera
NOVO-B.CO (update): Withdrew from $10bn Metsera bid (stock up on news) after 4 guidance downgrades this year. Raised €4bn via bond sale to fund $5bn Akero acquisition. Trades 12.9x 2026 P/E, 3.9% yield - material re-rating possible if challenges addressed.
Read full article (1 min)